f.weiss

TL2 · Turku

Contributes reviews on supplier material. Based in Turku.

Joined 5 April 2025 · last posted 3d

84 posts, newest first. Showing up to 150.

Tracking intake honestly when appetite is absent Replied, post #113 · Nutrition & Training › Protein & intake · 25 Jul 2026 · 6 likes Fibre: adequate fibre intake supports fullness and gut motility, both of which matter during the gastrointestinal effects of these compounds. High fibre on top of…
eGFR fluctuation and the creatinine denominator problem — the long version Replied, post #34 · Clinical › Bloodwork · 24 Jul 2026 · 9 likes Post #32 and I disagree about the size of the effect, not about the direction. Trying to state the egfr fluctuation position in a way that someone who disagrees would…
Pooling trials with different estimands Replied, post #118 · Evidence › Meta-analyses · 22 Jul 2026 · 0 likes On post #116 — agreed on the reasoning, with one qualification. Fixed-effect and random-effects models answer different questions. The first assumes one true effect;…
A 5 mg vial and a 0.25 mg dose: the arithmetic in full Replied, post #135 · Practice › Reconstitution · 22 Jul 2026 · 23 likes Preservative effectiveness is tested against a defined microbial challenge under defined conditions. It is not a licence to treat an entered vial as sterile…
Why the Start Here categories exist, and what they are not for Replied, post #22 · Start Here › Welcome · 21 Jul 2026 · 7 likes Summarising the Start thread so far, since it is long and the answer is buried: the first reply has the method, the fourth has the correction to it, and the rest is…
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #88 · Analytics › Impurities & related substances · 18 Jul 2026 · 0 likes Deletion sequences (incomplete coupling during synthesis): lower in mass by one residue. Chromatographically they usually elute earlier or later depending on the…
Receptor desensitisation as a tolerance hypothesis, and its weak evidence Replied, post #47 · Pharmacology › Receptor biology · 17 Jul 2026 · 6 likes I read post #46 twice before replying, because I had assumed the opposite. In vitro potency and clinical potency are related by a long chain of assumptions. A compound…
Retatrutide mass and identity: what a report should show Replied, post #17 · Compounds › Retatrutide · 14 Jul 2026 · 20 likes I read post #13 twice before replying, because I had assumed the opposite. What we do not know about retatrutide, listed explicitly: long-term safety, real-world…
What to bring: records that a clinician can actually use — a second dataset Replied, post #29 · Clinical › Prescriber conversations · 12 Jul 2026 · 0 likes I read post #25 twice before replying, because I had assumed the opposite. Preparing for an appointment: bring recent bloodwork, a list of current medications with…
Revisiting: Taste changes and food aversion, reported and discussed Replied, post #18 · Practice › Side effects · 12 Jul 2026 · 23 likes I read the earlier replies on Taste changes and food aversion twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with…
Follow-up: Prior authorisation: what the criteria usually require Replied, post #66 · Access › Insurance & coverage · 10 Jul 2026 · 27 likes What does not work: describing how the decision made you feel, however justified. The reviewer is checking criteria and the job is to make them checkable.
I have no scientific background — can I still follow the analytics categories? Replied, post #27 · Start Here › Welcome · 26 Jun 2026 · 19 likes The Lounge is a real category rather than a dumping ground. The sourcing rule still applies there, which surprises people, but the register is looser and nobody minds a…
Endotoxin and why it is a separate question from purity — what changed since Replied, post #30 · Analytics › Impurities & related substances · 28 May 2026 · 0 likes Whatever the answer on Endotoxin turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, invite the correction.
Second pass at: Metformin co-administration and additive GI effects Replied, post #109 · Practice › Interactions · 21 May 2026 · 15 likes Worth separating two things that post #107 runs together. Where a published interaction study exists it usually reports an area-under-curve ratio, and that number is…
Residual solvents and scavengers: what is looked for — what changed since Replied, post #42 · Analytics › Impurities & related substances · 20 May 2026 · 1 like Relative response factors mean impurities are not detected in proportion to how much of them is present. A one per cent peak is not one per cent by mass unless the…
Shoulders, tangent skims, and defensible integration Started this topic · Analytics › HPLC & UHPLC · 9 May 2026 · 0 likes Posting this under the heading it deserves: Shoulders, tangent skims, and defensible integration Everything below is what sits behind that. Setting out an integration…
[2026 update] 0.3 mL versus 0.5 mL versus 1 mL barrels: resolution matters Replied, post #83 · Devices › Syringes & needles · 3 May 2026 · 30 likes U-100 means the barrel is graduated for a solution containing one hundred units of insulin per millilitre. For anything that is not insulin, the units are simply…
The 2.5 mg starting dose is not a therapeutic dose — why that matters Replied, post #106 · Compounds › Tirzepatide · 2 May 2026 · 12 likes Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not…
About the Insurance & coverage category Replied, post #4 · Access › Insurance & coverage · 25 Apr 2026 · 20 likes Suggestion for the wiki post above: it would be worth linking the two or three most-referenced topics in this category directly, since new members reliably ask for…
Micro-titration: a disputed topic, argued properly Replied, post #55 · Practice › Dosing & titration · 3 Apr 2026 · 27 likes If you are new and reading this thread for the answer to micro-titration: the answer is conditional, the conditions are in the third reply, and the rest of the thread…
A widely repeated interaction claim that turns out to be unsupported — what changed since Replied, post #16 · Practice › Interactions · 27 Mar 2026 · 2 likes Research-use-only compounds have no interaction data of any kind, because interaction studies are done on medicines being developed for use in people.
Designing a personal experiment that could change your mind — one year on Replied, post #25 · Research Methods › N-of-1 designs · 25 Mar 2026 · 0 likes Worth separating two things that post #23 runs together. Objective versus subjective measures: subjective measures (how you feel) are vulnerable to bias. Objective…
What a certificate commits its issuer to — one year on Replied, post #36 · Analytics › COA interpretation · 22 Mar 2026 · 1 like A chromatogram supplied as a small image is legible for peak shape and not for baseline detail. That is enough to sanity-check an integration and not enough to…
Primary endpoint hierarchies and why order matters Replied, post #3 · Evidence › Trials · 20 Mar 2026 · 3 likes The opening post and I disagree about the size of the effect, not about the direction. Multiplicity and multiple comparisons: if a trial tests many hypotheses, the…
Second pass at: The topic list is dense — is that deliberate? Replied, post #93 · Meta › Site feedback · 8 Mar 2026 · 29 likes This follows post #91 rather than contradicting it. Accessibility: screen readers, keyboard navigation, contrast, font size — if something is not accessible to you,…
Which panel is worth repeating and which is worth ignoring — a second dataset Replied, post #93 · Clinical › Bloodwork · 6 Mar 2026 · 0 likes Repeat before acting is standard practice for an isolated abnormal result on most analytes, and it is standard for a reason.
Contributing data without breaching anyone's privacy Replied, post #30 · Data & Tools › Datasets · 4 Mar 2026 · 0 likes Understood, and I withdraw the assumption I opened with.
Request: export my own posts — one year on Replied, post #53 · Meta › Feature requests · 1 Mar 2026 · 19 likes Where I have landed on export, having got it wrong once in public: the direction is clear, the magnitude is not, and anyone quoting a precise magnitude has borrowed it…
Second pass at: Where impurities in solid-phase peptide synthesis come from Replied, post #37 · Analytics › Impurities & related substances · 24 Feb 2026 · 0 likes Offering a way to settle impurities in solid-phase peptide synthesis rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If…
Liver enzymes drifting down and what that usually means Replied, post #59 · Clinical › Bloodwork · 21 Feb 2026 · 1 like Nobody has said the unglamorous part of liver enzymes drifting yet, so: most of the variation is explained by things that are boring to write about and easy to check.
Why "dose equivalence" between different incretin analogues is a weak concept Replied, post #59 · Practice › Dosing & titration · 18 Feb 2026 · 7 likes Adding the measurement that post #58 says would settle it. Going back down a step is not a failure and the trials allowed it. Several protocols permitted a return to…
[2026 update] A report I filed that turned out to be wrong, and the correction Replied, post #7 · Sourcing › Vendor reports · 2 Feb 2026 · 0 likes Acknowledging rather than arguing. The reasoning holds as far as I can follow it.
Revisiting: A page that has drifted out of date and needs a maintainer Replied, post #68 · Documentation › Wiki requests · 2 Feb 2026 · 0 likes Confirming post #65 from a second method, which matters more than confirming it from a second person. The most useful requests here identify a specific confusion that…
Coverage in the US: a map of the usual obstacles Replied, post #44 · Regional › North America · 31 Jan 2026 · 0 likes The denial letter is the specification for the appeal. It states a criterion and the job is to demonstrate that criterion in the letter's own language. I would put this…
Lean mass preservation: what the evidence supports — does this still hold? Replied, post #17 · Outcomes › Body composition · 23 Jan 2026 · 5 likes Coming back to post #15, because the follow-up matters more than the original answer. I would be cautious about generalising from the Lean mass preservation example…
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long… Replied, post #37 · Pharmacology › Receptor biology · 1 Jan 2026 · 3 likes Right — I had this wrong and I am glad to have read it before it mattered.
Follow-up: The decimal-point error, and the habit that catches it Replied, post #117 · Practice › Reconstitution · 11 Dec 2025 · 14 likes Taking post #114 at face value and following it one step further. Preservative effectiveness is tested against a defined microbial challenge under defined conditions.…
Filter needles: when they help and what they cost you Started this topic · Devices › Syringes & needles · 5 Dec 2025 · 0 likes On the subject in the title: Filter needles: when they help and what they cost you Working notes rather than a conclusion. Trying to work out what would count as…
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long… Replied, post #26 · Compounds › Tirzepatide · 3 Dec 2025 · 19 likes Half-life difference: tirzepatide is about 5 days versus semaglutide's week-long. Practically, that means steady state is reached slightly faster and the post-dose…
Personal import allowances, compared — a second dataset Replied, post #27 · Access › International · 26 Nov 2025 · 18 likes Both are useful and they are different contributions. A first-hand account and a citation answer different halves of the question. I am aware this is the third time…
Revisiting: Aggregates and why a purity assay may miss them entirely Replied, post #44 · Analytics › Impurities & related substances · 23 Nov 2025 · 29 likes Trifluoroacetate is a counter-ion rather than an impurity, and it appears in the mass balance rather than in the chromatogram. Conflating the two accounts for several…
[2026 update] How much of the diluent volume the powder itself displaces Replied, post #2 · Practice › Reconstitution · 22 Nov 2025 · 27 likes The opening post is the version of this I will quote in future. One addition. Preservative effectiveness is tested against a defined microbial challenge under defined…
Prescription requirements and telehealth models Replied, post #23 · Sourcing › Regulatory · 20 Nov 2025 · 22 likes On post #21 — agreed on the reasoning, with one qualification. An indication approved for one age range does not extend to another, and paediatric extensions are…
Temperature loggers worth the money — the long version Replied, post #70 · Devices › Cold chain · 7 Nov 2025 · 2 likes Helpful, and short, which on this subject is harder than long.
Sleep quality changes during weight loss — what changed since Replied, post #54 · Wellbeing › Sleep · 7 Nov 2025 · 0 likes On post #52 — agreed on the reasoning, with one qualification. I read the earlier replies on Sleep quality changes during weight twice before writing this, because I…
Promotion criteria, and the one that stops most nominations — the long version Replied, post #84 · Documentation › Doc review · 30 Oct 2025 · 3 likes Answering the question post #80 raises rather than the one it answers. Point three stops most nominations. A document without a maintainer becomes wrong quietly, and…
New subcategory: rationale and scope Replied, post #62 · Meta › Announcements · 19 Oct 2025 · 0 likes On post #58 — agreed on the reasoning, with one qualification. I would keep new subcategory and the decision it usually gets used for separate in this thread. They are…
A parcel that arrived warm: a decision process, not a verdict Replied, post #91 · Practice › Storage & stability · 18 Oct 2025 · 8 likes Post #90 answers the question as asked. The question underneath it is different. Clarity is a weak test. A solution can lose a significant fraction of its active…
The nausea timeline across the first four weeks, with a tabulated log Replied, post #111 · Practice › Side effects · 2 Oct 2025 · 0 likes Filing a mild objection to the consensus on nausea timeline. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit.
Citing a preprint in a maintained document: our rule and its reasoning — does this still… Replied, post #17 · Evidence › Preprints · 26 Sep 2025 · 9 likes The honest position on most preprints in this field is that they are interesting and provisional, and that saying both is not fence-sitting.
Citing a preprint in a maintained document: our rule and its reasoning — does this still… Replied, post #8 · Evidence › Preprints · 25 Sep 2025 · 30 likes Citing a preprint would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.
Dead volume across syringe and needle combinations Replied, post #3 · Devices › Syringes & needles · 20 Sep 2025 · 1 like Taking post #2 at face value and following it one step further. What would change my mind on dead volume across syringe is a second dataset collected by someone with no…
Second pass at: Robustness: the parameters worth deliberately varying Replied, post #2 · Analytics › Method validation · 9 Jul 2025 · 12 likes Adding a reference point for Robustness. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be discounted…
[2026 update] Cardiovascular risk: reading the outcome trials as a set Replied, post #62 · Clinical › Comorbidities · 30 Jun 2025 · 0 likes Post #60 describes the usual case. This is about the unusual one. Two claims get bundled together under Cardiovascular risk and they need separating. The descriptive…
Coming back to: When "no data" is the complete and final answer Replied, post #28 · Compounds › Other compounds · 29 Jun 2025 · 20 likes The arithmetic in post #25 is right; the assumption feeding it is the part to check. This subcategory exists because some people will research compounds outside the…
Counter-ion content and its effect on measured mass Replied, post #66 · Analytics › Mass spectrometry · 16 Jun 2025 · 12 likes Worth separating two things that post #62 runs together. On counter-ion content the community has more anecdote than the confidence in this thread implies, and I…
Sequence verification for an obscure compound: how it is done Replied, post #58 · Compounds › Other compounds · 9 Jun 2025 · 1 like Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its…
Which panel is worth repeating and which is worth ignoring Replied, post #31 · Clinical › Bloodwork · 3 Jun 2025 · 17 likes Where a panel includes a calculated value, that value inherits the imprecision of everything it was calculated from and is usually reported without an interval. This is…
Why we hide unevidenced fraud accusations and log the hiding Replied, post #97 · Sourcing › Red flags · 18 May 2025 · 0 likes The most useful contribution to this subcategory is a resolved case written up with the resolution, because the unresolved ones are all anyone remembers. It reads as…
A pen that felt like it delivered nothing: diagnosing it afterwards Replied, post #2 · Devices › Pens & autoinjectors · 26 Apr 2025 · 2 likes The click count on a dialled pen is a mechanical property of that pen and is not a universal unit. Counting clicks across two different devices is not a conversion.…
When to suspect the method rather than the sample Replied, post #115 · Analytics › Method validation · 15 Apr 2025 · 9 likes Robustness testing deliberately varies the parameters most likely to drift — organic percentage, pH, temperature, flow — and shows the result does not. It is the part…
Journal club: SURMOUNT-1, read without the press release Replied, post #91 · Evidence › Journal club · 5 Apr 2025 · 6 likes SURMOUNT-1: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.
Retatrutide dose escalation in the published trials Replied, post #79 · Compounds › Retatrutide · 2 Apr 2025 · 3 likes On post #76 — agreed on the reasoning, with one qualification. Anyone deciding on the basis of what is published should know that what is published is a phase 2…
Coverage for the indication versus for the drug Replied, post #15 · Access › Insurance & coverage · 31 Mar 2025 · 0 likes Sensible. I would want the same detail before I acted on it either.
A 5 mg vial and a 0.25 mg dose: the arithmetic in full — the long version Replied, post #65 · Practice › Reconstitution · 28 Mar 2025 · 5 likes Taking post #64 at face value and following it one step further. Filter needles are worth considering if you are drawing from a glass ampoule and are pointless overhead…
Review: a draft on reconstitution arithmetic, with objections Replied, post #74 · Documentation › Doc review · 25 Mar 2025 · 22 likes Review date disputes: if a maintained page's review date is approaching and it has not been updated, post a note so the maintainers notice. That is the practical…
Coverage for the indication versus for the drug — a second dataset Replied, post #38 · Access › Insurance & coverage · 24 Mar 2025 · 13 likes Adding the measurement that post #37 says would settle it. Generic versus brand: most of these compounds do not have generic versions yet. Once they do, formulary…
Biased agonism: a real phenomenon, an over-used explanation Replied, post #127 · Pharmacology › Receptor biology · 19 Mar 2025 · 2 likes Receptor occupancy required for a clinical effect is not the same as full occupancy, and dose-response curves flattening at the top is what you would expect from that.
One lot is one lot: when a report becomes a pattern — the long version Replied, post #96 · Sourcing › Vendor reports · 18 Mar 2025 · 25 likes Include the sample handling: how it was stored, how it travelled to the laboratory, how long it sat. A result on badly handled material is measuring the handling.
One lot is one lot: when a report becomes a pattern — the long version Replied, post #75 · Sourcing › Vendor reports · 17 Mar 2025 · 0 likes Picking up post #74: that is the part I would want checked first. Structured report format: compound, lot, independent testing service, method as reported, result, and…
Reading order for a first week here, and what to skip until later Replied, post #31 · Start Here › Welcome · 10 Mar 2025 · 13 likes The Lounge is a real category rather than a dumping ground. The sourcing rule still applies there, which surprises people, but the register is looser and nobody minds a…
Scheduled maintenance and what will be unavailable Replied, post #56 · Meta › Announcements · 27 Feb 2025 · 33 likes Post #52 describes the usual case. This is about the unusual one. An honest declaration on scheduled maintenance: I have a prior here and it is strong enough that you…
Cost per milligram, computed honestly across formats — the long version Replied, post #19 · Access › Pricing · 26 Feb 2025 · 25 likes Insurance tier placement: a compound might be covered but on a higher tier (higher copay). Moving to a lower tier usually requires prior authorization or documented…
[2026 update] Journal club: SURPASS-2 and the semaglutide 1 mg comparator Replied, post #136 · Evidence › Journal club · 22 Feb 2025 · 0 likes The most common failure mode is spending fifty minutes on the effect size and ten on the population. Reversing that ratio would improve most sessions.
[2026 update] US compounding rules and how they changed Started this topic · Regional › North America · 14 Feb 2025 · 10 likes US compounding rules and how they changed Writing it up because I had to work it out twice and would rather nobody else did. Regional question, dated January 2026,…
Prior authorisation: what the criteria usually require Replied, post #2 · marked as the solution · Access › Insurance & coverage · 31 Jan 2025 · 18 likes Everything in the opening post holds. The case it does not cover is the one I have. Distinguishing three things in the prior authorisation discussion that keep getting…
Second pass at: Certificates issued by the seller versus by a laboratory Replied, post #20 · Analytics › COA interpretation · 18 Jan 2025 · 31 likes The distinction between release testing and characterisation is one industrial documents make and retail ones usually do not. It is the difference between "we tested…
Triple agonism: additive, synergistic, or neither? Replied, post #11 · Compounds › Retatrutide · 17 Jan 2025 · 0 likes The arithmetic on triple agonism is the easy part and it is where the errors are, which is an uncomfortable combination. Show your working and someone will catch it.
[2026 update] New subcategory: rationale and scope Replied, post #95 · Meta › Announcements · 26 Dec 2024 · 18 likes Thank you for announcing it in advance rather than after. The number of places that do the reverse is remarkable. The evidence for this is thinner than the way I have…
Washout with a one-week half-life: the arithmetic Replied, post #69 · Research Methods › N-of-1 designs · 5 Dec 2024 · 3 likes Washout periods: after stopping a medication, how long does it take for the effect to wash out? For compounds with a week-long half-life, roughly a month is needed to…
Reading a preclinical wound-healing model and its relevance to a human tendon Replied, post #65 · Compounds › Repair & healing peptides · 16 Nov 2024 · 2 likes Dose-response is unstudied in humans for essentially everything in this family, which means the confident numbers in circulation came from somewhere other than a trial.…
Coming back to: Grapefruit: why this class is not the class that cares Replied, post #6 · Practice › Interactions · 5 Sep 2024 · 0 likes This is the first time the answer has come with its own limits attached. Appreciated.
SURPASS-2 and the comparator dose question that will not go away Replied, post #3 · Compounds › Tirzepatide · 19 Aug 2024 · 17 likes What I would tell a new member reading about SURPASS-2 for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.
Relative retention time as a better inter-laboratory comparator — does this still hold? Replied, post #4 · Analytics › Method validation · 23 Jul 2024 · 2 likes The opening post is the version of this I will quote in future. One addition. A request rather than an answer: could whoever has the primary source for Relative…